Influenza A virus subtype H1N1

Cidara Therapeutics Announces Agreement with Janssen to Develop and Commercialize AVCs for the Prevention and Treatment of Influenza

Retrieved on: 
Monday, April 5, 2021
Articles, Health, Medical specialties, Flu season, Influenza, Seasonality, Severe acute respiratory syndrome, Antiviral drug, Pandemic, Influenza A virus subtype H1N1

Cidara will receive an upfront payment of $27 million and Janssen will fund all future research, development, manufacturing and commercialization for CD388.

Key Points: 
  • Cidara will receive an upfront payment of $27 million and Janssen will fund all future research, development, manufacturing and commercialization for CD388.
  • Importantly, this agreement validates our Cloudbreak antiviral platform as we continue to advance our AVC programs in RSV, HIV and SARS-CoV-2.
  • AVCs being studied for the prevention and treatment of seasonal and pandemic influenza have the potential to deliver universal protection for an entire flu season.
  • Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections.

HI-NANO: Hisense's new technology inactivates COVID-19 with a rate up to 93.54%

Retrieved on: 
Tuesday, March 30, 2021
Influenza A virus subtype H1N1, Orthomyxoviridae, Influenza, Biology

Also, verified by the world's leading testing group SGS's, HI-NANO can effectively remove over 99.37% of the H1N1 influenza virus in 2 hours ina30 m3 chamber.

Key Points: 
  • Also, verified by the world's leading testing group SGS's, HI-NANO can effectively remove over 99.37% of the H1N1 influenza virus in 2 hours ina30 m3 chamber.
  • As a responsible tech company, Hisense (000921.SZ)aims to create healthy and clean air for consumers worldwide.
  • A viral clearance performance of 90% removal rate in one hour and 99% in two hours has been verified.
  • Hisense believes that technology can make a significant impact on protecting the air we share and keeping it healthy and clean for all.

U.S. employers making moves to facilitate COVID-19 vaccination of employees, Willis Towers Watson survey finds

Retrieved on: 
Thursday, March 25, 2021
Service companies, Consulting, Vaccination, Companies, Towers Watson, Willis Group, Vaccine, Influenza A virus subtype H1N1

Employers understand that by taking an active part in supporting the vaccination of employees, they can play a crucial role in ending the pandemic, said Jeff Levin-Scherz, M.D., population health leader, Willis Towers Watson.

Key Points: 
  • Employers understand that by taking an active part in supporting the vaccination of employees, they can play a crucial role in ending the pandemic, said Jeff Levin-Scherz, M.D., population health leader, Willis Towers Watson.
  • The survey identified various actions employers are taking to facilitate employee vaccination:
    Six in 10 employers (60%) have communicated to employees the value of vaccines; another 35% are planning or considering doing so.
  • Employers are eager to improve vaccination rates, contain any further spread of the virus and bring employees back to work, said Chantell Sell Reagan, national pharmacy community clinical leader, Willis Towers Watson.
  • With roots dating to 1828, Willis Towers Watson has 45,000 employees serving more than 140 countries and markets.

Abbott Announces its Pandemic Defense Coalition: A Global Network of Expert Collaborators Designed To Help Prevent Future Pandemics, Currently Searching for COVID-19 Variants

Retrieved on: 
Thursday, March 11, 2021
Articles, Health, Global health, Epidemiology, Pandemics, Infectious diseases, Influenza A virus subtype H1N1, Virus, Pandemic prevention

The coalition is designed to help the global scientific and health community identify new viral threats, take quick action when one is discovered, and help prevent future pandemics.

Key Points: 
  • The coalition is designed to help the global scientific and health community identify new viral threats, take quick action when one is discovered, and help prevent future pandemics.
  • This program expands upon the viral surveillance and discovery work that Abbott has performed over the last three decades.
  • Understanding what pathogenic threats are emerging will help us test, diagnose and hopefully help prevent the next pandemic."
  • The new Abbott Pandemic Defense Coalition consists of global collaborators specializing in virus identification, surveillance, sample collection, testing and data analytics.

ACLIV Wins Certification for Killing COVID-19 Virus by 99.9% Within 30 Minutes From Antiviral Testing Agency in France

Retrieved on: 
Thursday, March 11, 2021
Research, Mobile, Wireless, Hardware, Pharmaceutical, Technology, Medical devices, Infectious diseases, Semiconductor, Science, Chemicals, Plastics, Other Technology, Health, Manufacturing, Zoonoses, Health, Articles, Pandemics, Antiviral drug, Biocides, Virus, Coronavirus disease, Influenza A virus subtype H1N1

: 21-1634) from an antiviral testing agency in France, confirming that its antiviral film ACLIV can kill COVID-19 virus by 99.9% within 30 minutes.

Key Points: 
  • : 21-1634) from an antiviral testing agency in France, confirming that its antiviral film ACLIV can kill COVID-19 virus by 99.9% within 30 minutes.
  • At the test conducted targeting the COVID-19 virus, ACLIV antiviral film killed 99.9% of the virus within 30 minutes.
  • This is by far the most outstanding result among those of antiviral tests conducted on the COVID-19 virus so far.
  • Previously, Hexis of France had produced the best result of killing the virus in approximately one hour.

Survey Finds Men More Concerned About Coronavirus Than Women

Retrieved on: 
Thursday, March 4, 2021
Public health, Hygiene, Sanitation, Euthenics, Prevention, Hand washing, Wash, Influenza A virus subtype H1N1

MENOMONEE FALLS, Wis., March 4, 2021 /PRNewswire/ --According to a national survey, men are significantly more concerned about contracting the coronavirus than women.

Key Points: 
  • MENOMONEE FALLS, Wis., March 4, 2021 /PRNewswire/ --According to a national survey, men are significantly more concerned about contracting the coronavirus than women.
  • The Healthy Handwashing Survey conducted by Bradley Corporation found that 62% of men are "very concerned" about getting the virus compared to 45% of women who expressed the same level of trepidation.
  • That's significant since men have consistently underperformed women in handwashing diligence during the past 12 years that the Healthy Handwashing Survey has been conducted.
  • When asked about the flu virus, 51% of men said they were "very concerned" about contracting it versus just 38% of women who felt the same way.

Three Canadian studies will help determine how many teachers may have had COVID-19

Retrieved on: 
Thursday, March 4, 2021
Articles, Health, Occupational safety and health, Coronaviridae, Coronavirus disease, Public health, Zoonoses, Severe acute respiratory syndrome coronavirus, Vaccination, Influenza A virus subtype H1N1, COVID-19 vaccine, BBIBP-CorV

The studies will also evaluate the effects of the pandemic on teachers mental health.

Key Points: 
  • The studies will also evaluate the effects of the pandemic on teachers mental health.
  • All three studies will ask teachers and education workers for blood samples to establish how many have antibodies to SARS-CoV-2, which would indicate a previous COVID-19 infection.
  • When a vaccine becomes available to education workers, these studies will determine how many teachers agree to be vaccinated and whether antibodies are detected in their blood after vaccination at several points in time.
  • The Ontario study aims to enroll up to 7,000 teachers and education workers and will follow participants for 12 months to determine the factors associated with infection.

African swine fever: devising an ‘exit strategy’ for affected countries

Retrieved on: 
Thursday, March 4, 2021
Animal virology, African swine fever virus, Influenza A virus subtype H1N1, Classical swine fever

EFSA has devised surveillance strategies that will help countries affected by African swine fever (ASF) to determine when the virus has stopped circulating among their wild boar populations.

Key Points: 
  • EFSA has devised surveillance strategies that will help countries affected by African swine fever (ASF) to determine when the virus has stopped circulating among their wild boar populations.
  • The scientific opinion recommends an exit strategy comprising two phases: a period of routine surveillance of wild boar (the screening phase) followed by a shorter period of intense surveillance (the confirmation phase).
  • Modelling demonstrated that:

    The opinion gives practical examples of how to apply the exit strategy to both large and small affected areas.

  • It also makes recommendations on the minimum monitoring periods needed to make the strategy effective.

Innovative Cardiovascular Solutions Announces Successful First Cases in European Clinical Study of its Next Generation EMBLOK™ Embolic Protection System

Retrieved on: 
Tuesday, March 2, 2021
Influenza A virus subtype H1N1

"We anticipate that 2021 will be an exceptional year for ICS as we launch our US IDE clinical study and continue to demonstrate the performance of the EMBLOK Embolic Protection System, highlighting the clinical advantage of complete embolic protection."

Key Points: 
  • "We anticipate that 2021 will be an exceptional year for ICS as we launch our US IDE clinical study and continue to demonstrate the performance of the EMBLOK Embolic Protection System, highlighting the clinical advantage of complete embolic protection."
  • Innovative Cardiovascular Solutions is privately held company pioneering novel solutions for embolic protection during structural heart and vascular interventions.
  • The complete EMBLOK system, including the embolic filter and pigtail catheter may be delivered through a single femoral access location.
  • The EMBLOK Embolic Protection System is not yet commercially available and is intended for investigational use only.

InventHelp Inventor Develops a Device to Sanitize Indoor Air (AVZ-935)

Retrieved on: 
Monday, February 22, 2021
Respiratory therapy, Health, Asthma, Influenza A virus subtype H1N1, Indoor air quality, Clinical medicine, Articles

PITTSBURGH, Feb. 22, 2021 /PRNewswire/ -- "Since illnesses such as asthma and H1N1 can result from contaminated air, I decided that there needed to be a way to make indoor air more sanitary," said an inventor from Memphis, Tenn.

Key Points: 
  • PITTSBURGH, Feb. 22, 2021 /PRNewswire/ -- "Since illnesses such as asthma and H1N1 can result from contaminated air, I decided that there needed to be a way to make indoor air more sanitary," said an inventor from Memphis, Tenn.
  • Ideal for all households, the easy-to-use SANTI BOX provides an easy way to sanitize indoor air in order to promote good respiratory health.
  • As a result, it helps avoid the onset of asthma, H1N1 and other illnesses.
  • The original design was submitted to the Telemarketing office of InventHelp.